Cullinan Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
15/05/2024 22:35
* Cullinan Therapeutics Inc CGEM.OQ reported a quarterly
adjusted loss of 86 cents per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-1.42. The mean expectation of nine analysts
for the quarter was for a loss of 99 cents per share. Wall
Street expected results to range from $-1.42 to -72 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Cullinan Therapeutics Inc's reported EPS for the quarter
was a
loss of 86 cents.
* The company reported a quarterly loss of $37.15 million.
* Cullinan Therapeutics Inc shares had risen by 54.8% this
quarter and gained 158.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.7%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Cullinan
Therapeutics Inc is $30.00
This summary was machine generated from LSEG data May 15 at
09:34 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.99 -0.86 Beat
Dec. 31 2023 -0.96 -0.54 Beat
Sep. 30 2023 -0.92 -0.91 Beat
Jun. 30 2023 -0.97 -0.82 Beat